Cantargia AB (publ) (CANTA.ST)
ValueMarkers Composite Index
81% below intrinsic value ($2)
Cantargia AB (publ) (CANTA.ST) — VMCI valuation read
Cantargia AB (publ) (CANTA.ST) carries a VMCI composite of 66/100, 16 points above the Healthcare sector median of 50. Among mid-cap names, that gap places CANTA.ST in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The CANTA.ST insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads CANTA.ST trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.4x is the rate-sensitivity line to watch, the line to track on Cantargia AB (publ)'s next 10-Q.
CANTA.ST rose 1.0% over the trailing 7 days, with a -16.8% read on a 30-day basis.
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.